|
|
Volumn 39, Issue 1-2, 2001, Pages 181-194
|
|
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
a
b
BIOGEN
(United States)
|
|
Author keywords
90Y Zevalin; Dosimetry; IDEC Y2B8; Non Hodgkin's lymphoma; Radioimmunotherapy; Rituximab
|
|
Indexed keywords
IBRITUMOMAB TIUXETAN;
INDIUM 111;
MONOCLONAL ANTIBODY;
RITUXIMAB;
UNCLASSIFIED DRUG;
YTTRIUM 90;
B CELL LYMPHOMA;
BLOOD TOXICITY;
BONE MARROW;
CLINICAL TRIAL;
COMPUTER PROGRAM;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSIMETRY;
FOLLICULAR LYMPHOMA;
HALF LIFE TIME;
HUMAN;
MAJOR CLINICAL STUDY;
MALIGNANT TRANSFORMATION;
MULTICENTER STUDY;
NONHODGKIN LYMPHOMA;
PHASE 3 CLINICAL TRIAL;
RADIATION ABSORPTION;
RADIOIMMUNOTHERAPY;
RANDOMIZED CONTROLLED TRIAL;
RELAPSE;
TISSUE DISTRIBUTION;
URINARY EXCRETION;
WHOLE BODY RADIATION;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
HUMANS;
LYMPHOMA, B-CELL;
PROSPECTIVE STUDIES;
RADIOIMMUNOTHERAPY;
TISSUE DISTRIBUTION;
TOMOGRAPHY, EMISSION-COMPUTED;
TREATMENT OUTCOME;
YTTRIUM RADIOISOTOPES;
|
|
EID: 0034979977
PISSN: 10408428
EISSN: None
Source Type: Journal
DOI: 10.1016/S1040-8428(01)00107-X Document Type: Conference Paper |
|
Times cited : (174)
|
|
References (21)
|
